soul trial oral semaglutide cardiovascular outcomes 2024 nejm results 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants Oral Semaglutide Reduces CV Events
Description
Waist circumference was also measured, and decreased more in those treated with 25 mg and 50 mg than with 14 mg
With insurance, your cost could be as low as your standard copay, potentially even $0, depending on your plan
Semaglutide lowers the production of glucagon, which prevents the liver from releasing too much sugar into the blood
Finally, insurance coverage is unlikely to offset costs for most patients
